Organisation paid for research Program year 2022 Source: CMS Open Payments

Blue Theory Clinical Trials LLC

Neither a doctor nor a teaching hospital

Research payments

$1,438,186

72 payments

Through program year 2022, Blue Theory Clinical Trials LLC is reported as receiving $1,438,186 in research payments, across 72 payments.

By program year

4 rows
Year Kind Amount Payments
2022 Research $19,424 6
2021 Research $200,352 15
2020 Research $247,765 25
2019 Research $970,645 26

Breakdown

Who paid Research payments · program years 2019–2022
  1. AstraZeneca Pharmaceuticals LP $991,109 59 payments
  2. AstraZeneca AB $440,564 8 payments
  3. GlaxoSmithKline, LLC. $3,763 2 payments
  4. Eisai Inc. $2,750 3 payments
Studies the money was for Research payments · program years 2019–2022
  1. A Phase 2b Randomised, Double Blind, Placebo Controlled, Parallel Arm, Multi Centre Study to Assess Efficacy and Safety of Multiple Dose Levels of AZD7594 DPI Given Once Daily for twelve weeks, compared to placebo, in Asthmatics symptomatic on low dose ICS $430,745 6 payments
  2. A Multicentre, Double-blind, Randomized, Placebo Controlled, Parallel Group, Phase 3, Safety Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents with Severe Uncontrolled Asthma. $281,699 6 payments
  3. A Randomized Double-Blind Parallel Group Multi-Center 24-Week Study Comparing the Efficacy and Safety of Three Doses of PT001 to Placebo and Open-label Spiriva Respimat in Subjects With Persistent Asthma $213,270 16 payments
  4. A Multicentre Randomized Double Blind Placebo Controlled Parallel Group Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults and Adolescents with Severe Uncontrolled Asthma $203,653 6 payments
  5. Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos) $134,424 5 payments
  6. A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler $66,620 4 payments
  7. A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Pharmacodynamic Effects of MEDI0382 in Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)/Non-alcoholic Steatohepatitis (NASH) $26,633 3 payments
  8. A 54 Week Treatment, Multicenter, Randomized, Double Blind, Double Dummy, Placebo and Active Controlled, Parallel Group Phase 2 Study to Assess the Efficacy and Safety of Brazikumab in Participants with Moderately to Severely Active Ulcerative Colitis $17,765 1 payment
  9. TA description Cardiovascular Renal and Metabolism Indications Chronic Kidney Disease Study status Ongoing Phase descripton Phase 3 Category R&D Sponsored Delivery model Internal $10,759 3 payments
  10. An Open-Label, Multi-Center, Phase I Study to Assess the Pharmacokinetics, Pharmacodynamics and Safety of 2-Week Treatment with Inhaled AZD7594 in Adolescents 12 to 17 years with Asthma (AMBER) $9,819 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2022

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record